William Blair downgraded Korro Bio (KRRO) to Market Perform from Outperform without a price target The disappointing data update from the REWRITE study of KRRO-110 “was a large blow to Korro shares,” the analyst tells investors in a research note. The firm says it downgrades the shares as Korro is now moving back to a preclinical-stage company.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Korro Bio downgraded to Market Perform from Strong Buy at Raymond James
- Korro Bio downgraded to Neutral from Buy at Chardan
- Korro Bio Reports Increased Losses Amid Strategic Developments
- Korro Bio downgraded to Hold from Buy at Clear Street